What are the key takeaways for Tilray Brands Inc ($TLRY)?

Expanded US craft brewing scale by completing the acquisition and initial integration of four craft beer brands from Molson Coors (Hop Valley, Terrapin, Revolver, and Atwater) in August 2024, cementing Tilray's status as the 5th largest craft brewer in the United States. First-quarter fiscal 2027 net revenue climbed 22.7% year-over-year to $257.15 million, driven primarily by double-digit expansion in the beverage alcohol portfolio and European medical cannabis demand. GAAP net loss registered at -$43.14 million with diluted EPS of -$0.32, reflecting an operating margin of -6.3% as general administrative costs and excise taxes outweighed gross profit improvements.

Tilray Brands Inc (TLRY) AI Stock Analysis & Earnings

Please enable JavaScript to continue using this application.

Latest Report Overview for Tilray Brands Inc ($TLRY)

AI-powered analysis of Tilray Brands Inc (TLRY) stock based on Q3 2026 financial data.

Published: October 18, 2026

Latest Report Overview

Tilray Brands Inc (TLRY) reported For the quarterly period ended August 31, 2026 (Issuer fiscal Q1 FY2027) revenue of $257 million with diluted EPS of $-0.32 and net income of -$43.1 million. Operating margin was -6.3%, and free cash flow was -$27.6 million for the period. Top-line performance during the quarter was anchored by substantial growth across the Beverage Alcohol segment, reflecting the integration and expanded commercial distribution of newly acquired craft brewery operations from Molson Coors (Hop Valley, Terrapin, Revolver, and Atwater) alongside previous brand additions from Anheuser-Busch InBev. In the Cannabis segment, growth was supported by international medical sales expansion, particularly in Germany following regulatory de-scheduling under the Cannabis Act (CanG), which offset ongoing price compression and high excise duty headwinds in the Canadian adult-use market. The Distribution segment anchored by CC Pharma maintained steady wholesale pharmaceutical volumes across German pharmacy accounts, while the Wellness segment saw stable demand for Manitoba Harvest hemp foods. Management commentary highlighted ongoing initiatives to extract operational synergies from recent beverage acquisitions, optimize manufacturing footprints, and scale national route-to-market partnerships across the United States. Management also underscored its strategy of utilizing its scaled craft brewing infrastructure to establish a federally compliant commercial bridgehead in the US market, positioning the business to distribute hemp-derived Delta-9 THC beverages and future cannabis products upon further regulatory liberalization. From a balance sheet perspective, Tilray closed the quarter with $214.96 million in cash and cash equivalents against $325.75 million in outstanding debt, resulting in a net debt position of $110.79 million. While gross profit advanced to $77.40 million, operating overhead, marketing investments, and facility costs drove an operating loss of -$16.20 million, keeping disciplined working capital stewardship and cash flow conversion as primary areas of operational focus.

Key Takeaways for Tilray Brands Inc

Expanded US craft brewing scale by completing the acquisition and initial integration of four craft beer brands from Molson Coors (Hop Valley, Terrapin, Revolver, and Atwater) in August 2024, cementing Tilray's status as the 5th largest craft brewer in the United States.
First-quarter fiscal 2027 net revenue climbed 22.7% year-over-year to $257.15 million, driven primarily by double-digit expansion in the beverage alcohol portfolio and European medical cannabis demand.
GAAP net loss registered at -$43.14 million with diluted EPS of -$0.32, reflecting an operating margin of -6.3% as general administrative costs and excise taxes outweighed gross profit improvements.
Free cash flow burn continued with a deficit of -$27.55 million in Q1 FY2027, bringing trailing twelve-month free cash flow to -$118.82 million and highlighting ongoing reliance on existing cash balances.
Gross margin expanded by 270 basis points year-over-year to 30.1%, benefiting from product mix shifts toward higher-margin craft beverage lines and supply chain efficiencies.
International medical cannabis revenues experienced positive momentum in Germany following the implementation of the Cannabis Act (CanG), driving increased patient prescriptions across Tilray's pharmacy distribution network.
Total debt stood at $325.75 million against cash and equivalents of $214.96 million, resulting in net debt of $110.79 million and maintaining a potential dilution overhang if operational cash flow does not reach breakeven.

What Does Tilray Brands Inc Do?

Tilray Brands, Inc. is a global consumer packaged goods (CPG) and lifestyle company operating four distinct business divisions: Beverage Alcohol, Cannabis, Distribution, and Wellness. In the Beverage Alcohol segment, the company produces, markets, and sells craft beers, ciders, craft spirits, and ready-to-drink beverages through well-known regional and national brands including SweetWater Brewing, Montauk Brewing, Shock Top, Breckenridge Brewery, 10 Barrel Brewing, Blue Point Brewing, Redhook, Widmer Brothers, Hop Valley, Terrapin, Revolver, Atwater, and Breckenridge Distillery. Tilray operates as the 5th largest craft brewing platform in the United States, utilizing extensive independent wholesale distributor relationships across the US three-tier distribution network. In the Cannabis segment, Tilray cultivates, processes, and markets medical and adult-use recreational cannabis products. In Canada, it offers dried flower, pre-rolls, vape cartridges, edibles, and concentrates under brands such as Good Supply, Redecan, Broken Coast, Solei, and Canaca to provincial wholesalers and authorized retailers. Globally, Tilray Medical supplies EU-GMP-certified medical cannabis to patients, physicians, pharmacies, and hospitals across Germany, the United Kingdom, Portugal, Poland, Italy, Australia, and New Zealand. The company's Distribution segment is centered on CC Pharma (Tilray Pharma), which distributes branded and generic pharmaceuticals, medical supplies, and medical cannabis to approximately 13,000 pharmacies across Germany and surrounding European nations. The Wellness segment operates primarily through Manitoba Harvest, a global pioneer in branded hemp foods, offering hemp hearts, hemp protein powders, and wellness supplements through major grocery, club, and natural retail accounts across North America. Tilray operates state-of-the-art cultivation, extraction, and manufacturing facilities in Canada, EU-GMP-certified greenhouse and indoor facilities in Cantanhede (Portugal) and Neumünster (Germany), and regional craft breweries across the United States. With annual net revenue approaching $1 billion ($963.1 million TTM) and thousands of employees worldwide, Tilray differentiates itself from pure-play cannabis operators through its diversified CPG structure, combining federally compliant US beverage cash flows, European pharmaceutical distribution, and Canadian recreational cannabis market share.

Growth Drivers for Tilray Brands Inc

Expanded US Craft Beverage Distribution: Driving increased retail chain distribution, taproom sales, and national draft placements for recently acquired craft beer brands (Hop Valley, Terrapin, Revolver, Atwater, Shock Top, Breckenridge, 10 Barrel) across the US three-tier distribution system.
German Medical Cannabis Deregulation: Capitalizing on Germany's Cannabis Act (CanG), which de-scheduled cannabis from the Narcotics Act, simplifying medical prescription protocols and expanding patient volume through CC Pharma's network of 13,000 pharmacies.
Commercialization of Hemp-Derived Delta-9 THC Beverages: Rolling out hemp-derived Delta-9 THC infused drinks and mocktails across legal US retail and direct-to-consumer channels, utilizing existing beverage manufacturing and distribution assets.
Canadian Adult-Use Product Innovation: Launching higher-margin cannabis format extensions, including infused pre-rolls, live resin vape cartridges, and premium flower strains under flagship brands Good Supply, Redecan, and Broken Coast.
International Medical Market Expansion: Scaling medical cannabis export sales into emerging European and international medical frameworks, including the United Kingdom, Poland, Italy, the Czech Republic, and Australia.
Brewing and Supply Chain Consolidation: Extracting operational cost synergies and procurement savings by consolidating brewing, packaging, and logistics across centralized regional production hubs.

Overview AI Summary Charts Financials Valuation

Based on August 31, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.

Latest Report Overview for Tilray Brands Inc ($TLRY)

Key Takeaways

1.Expanded US craft brewing scale by completing the acquisition and initial integration of four craft beer brands from Molson Coors (Hop Valley, Terrapin, Revolver, and Atwater) in August 2024, cementing Tilray's status as the 5th largest craft brewer in the United States.
2.First-quarter fiscal 2027 net revenue climbed 22.7% year-over-year to $257.15 million, driven primarily by double-digit expansion in the beverage alcohol portfolio and European medical cannabis demand.
3.GAAP net loss registered at -$43.14 million with diluted EPS of -$0.32, reflecting an operating margin of -6.3% as general administrative costs and excise taxes outweighed gross profit improvements.
4.Free cash flow burn continued with a deficit of -$27.55 million in Q1 FY2027, bringing trailing twelve-month free cash flow to -$118.82 million and highlighting ongoing reliance on existing cash balances.
5.Gross margin expanded by 270 basis points year-over-year to 30.1%, benefiting from product mix shifts toward higher-margin craft beverage lines and supply chain efficiencies.
6.International medical cannabis revenues experienced positive momentum in Germany following the implementation of the Cannabis Act (CanG), driving increased patient prescriptions across Tilray's pharmacy distribution network.
7.Total debt stood at $325.75 million against cash and equivalents of $214.96 million, resulting in net debt of $110.79 million and maintaining a potential dilution overhang if operational cash flow does not reach breakeven.

What They Do

How They Make Money

Tilray recognizes revenue under ASC 606 upon the transfer of control of promised goods to customers, which typically occurs upon shipment or delivery depending on contract terms. In the Canadian adult-use cannabis market, revenue is recorded net of provincial customer discounts, return allowances, and statutory excise duties. In the Beverage Alcohol segment, revenue is recognized upon product delivery to independent wholesale distributors, net of distributor promotional discounts, depletion allowances, and billbacks. In the Distribution segment, revenue is recognized upon the physical delivery of pharmaceuticals to retail pharmacies, while Wellness revenue is recognized upon product delivery to grocery, club, and mass merchandise retailers. Revenue is diversified across four core business pillars: Beverage Alcohol represents approximately 30% to 35% of consolidated net revenue, Cannabis contributes roughly 30% to 35% (split between Canadian adult-use, Canadian medical, and international medical cannabis), Distribution accounts for 25% to 30%, and Wellness generates approximately 6% to 8%. Contractual recurring revenue is negligible (less than 5% of total sales), as the business model depends almost entirely on wholesale purchase orders, distributor replenishment cycles, and consumer discretionary retail purchases, although medical cannabis patient prescriptions and routine pharmacy wholesale supply provide an underlying baseline of demand predictability. Revenue growth or contraction is driven by wholesale volume changes, retail distribution expansion (points of distribution and taproom traffic), international medical patient adoption in deregulating European markets, and strategic M&A additions in craft beer. Conversely, revenue is constrained by structural Canadian excise taxes (which absorb over 30% of gross recreational cannabis revenue), retail price compression in the Canadian cannabis sector, shifting consumer alcohol consumption preferences, and distributor inventory rebalancing cycles.

Competitive Position

Tilray occupies a multi-industry competitive position, contending with distinct sets of peers across its business segments. In the Canadian cannabis space, Tilray competes against licensed producers such as Canopy Growth Corporation, Cronos Group, SNDL Inc., Organigram Holdings, and Village Farms International, as well as a fragmented field of craft micro-cultivators and the illicit market. In Beverage Alcohol, it competes against major multinational brewing conglomerates like Anheuser-Busch InBev, Molson Coors, Constellation Brands, and Heineken, as well as leading independent craft brewers such as Boston Beer Company, Sierra Nevada Brewing, and New Belgium Brewing. In European medical cannabis, peers include Curaleaf International, Aurora Cannabis, and specialized pharmaceutical importers. Tilray's primary competitive advantages include its scaled US craft beer footprint, where it ranks as the 5th largest craft brewer with nationwide distributor alignment, and its established European medical cannabis infrastructure, featuring dual EU-GMP certified production sites in Portugal and Germany alongside CC Pharma's direct distribution access to ~13,000 German pharmacies. In Canada, Tilray maintains leading recreational market share across value and premium tiers through brand power in Good Supply, Redecan, and Broken Coast. From a relative valuation perspective, Tilray trades at an enterprise value to sales multiple of approximately 0.6x and a price-to-book multiple of ~0.3x, reflecting a steep valuation discount compared to traditional consumer packaged goods peers (which often trade above 2.0x EV/Sales) and mature alcohol brewers, yet roughly in line with distressed Canadian cannabis peers. Financial trends highlight robust top-line growth (+22.7% YoY) fueled by acquisitions, but gross margins of 30.1% remain well below consumer staples averages (40-50%), and negative operating margins (-6.3%) illustrate ongoing cost overhead and Canadian price compression. The durability of Tilray's competitive position is mixed. While its scale and European pharmaceutical footprint provide defensibility, switching costs for consumers in craft beer and adult-use cannabis are minimal, leaving products vulnerable to aggressive competitor discounting and shifting consumer taste preferences. Long-term sustainability hinges on management's ability to drive organic volume growth in craft beverages, capture market share in Germany's deregulating medical cannabis market, and extract cross-segment supply chain efficiencies.

Business Strategy & Moat

Tilray's strategic architecture centers on a diversified CPG platform designed to navigate cannabis regulatory fragmentation while establishing commercial scale. The company's economic moat is narrow and asset-based, derived from its installed craft beer distribution infrastructure and European medical licensing rather than deep consumer switching costs. Consumer switching costs in craft beer, hemp foods, and recreational cannabis are virtually non-existent, as consumers can effortlessly switch brands at retail. In contrast, in international medical cannabis, switching costs and regulatory barriers are moderately higher due to stringent EU-GMP pharmaceutical compliance, physician prescription habits, and specialized pharmacy distribution through CC Pharma. The strategic flywheel is predicated on leveraging federally legal US craft beverage assets to build manufacturing capacity, national distributor networks, and brand equity that can be quickly repurposed for hemp-derived Delta-9 THC beverages and future adult-use cannabis drinks once US federal laws permit. By operating across beverage alcohol, pharmaceutical distribution, and wellness, Tilray shares corporate infrastructure, procurement leverage, and logistics capabilities, while using CC Pharma as a commercial conduit to scale European medical cannabis formulations alongside traditional therapeutics. Capital allocation under Chairman and CEO Irwin Simon has focused heavily on external M&A, using cash, debt, and equity to acquire craft brewery assets from major brewers like Anheuser-Busch InBev and Molson Coors. While this acquisitive strategy has expanded revenue toward $1 billion, it has led to cumulative shareholder dilution, elevated debt levels ($325.75 million), negative returns on invested capital (-8.6% TTM), and ongoing negative free cash flow (-$27.55 million in Q1 FY2027). Management's near-term capital strategy must prioritize operational integration, working capital optimization, and debt reduction to establish financial self-sufficiency.

Industry Outlook

The global cannabis and beverage alcohol industries are undergoing significant structural and regulatory transitions. In North America, the Canadian adult-use cannabis sector remains highly competitive and mature, characterized by substantial market fragmentation, strict marketing and packaging restrictions, and punitive excise duties that absorb over 30% of gross recreational revenue. In the United States, federal cannabis reform remains constrained by legislative gridlock, although administrative proceedings regarding the potential reclassification of cannabis to Schedule III under the Controlled Substances Act offer longer-term potential for tax relief and regulatory clarity for plant-touching operators. In the US beverage alcohol sector, craft brewing faces macro headwinds characterized by mature volume trends, shifts in consumer demographics toward spirits and ready-to-drink (RTD) cocktails, and cautious discretionary consumer spending. Simultaneously, the emerging hemp-derived Delta-9 THC beverage category is experiencing rapid growth, though it faces an evolving and uncertain regulatory environment marked by state-level legislative debates and potential federal redefinitions under the reauthorization of the US Farm Bill. Europe represents the most promising growth frontier for medical cannabis. Germany's landmark implementation of the Cannabis Act (CanG) in 2024 removed cannabis from the German Narcotics Act, significantly reducing bureaucratic barriers for doctors prescribing medical cannabis and driving strong patient demand. Other European countries, including the United Kingdom, Poland, France, and the Czech Republic, continue to expand medical access frameworks, providing export opportunities for EU-GMP certified international operators.

Growth Drivers

•Expanded US Craft Beverage Distribution: Driving increased retail chain distribution, taproom sales, and national draft placements for recently acquired craft beer brands (Hop Valley, Terrapin, Revolver, Atwater, Shock Top, Breckenridge, 10 Barrel) across the US three-tier distribution system.
•German Medical Cannabis Deregulation: Capitalizing on Germany's Cannabis Act (CanG), which de-scheduled cannabis from the Narcotics Act, simplifying medical prescription protocols and expanding patient volume through CC Pharma's network of 13,000 pharmacies.
•Commercialization of Hemp-Derived Delta-9 THC Beverages: Rolling out hemp-derived Delta-9 THC infused drinks and mocktails across legal US retail and direct-to-consumer channels, utilizing existing beverage manufacturing and distribution assets.
•Canadian Adult-Use Product Innovation: Launching higher-margin cannabis format extensions, including infused pre-rolls, live resin vape cartridges, and premium flower strains under flagship brands Good Supply, Redecan, and Broken Coast.
•International Medical Market Expansion: Scaling medical cannabis export sales into emerging European and international medical frameworks, including the United Kingdom, Poland, Italy, the Czech Republic, and Australia.
•Brewing and Supply Chain Consolidation: Extracting operational cost synergies and procurement savings by consolidating brewing, packaging, and logistics across centralized regional production hubs.

Recent Developments

•Acquisition of Molson Coors Craft Breweries (August 2024): Completed the strategic acquisition of four craft beer brands and brewing operations from Molson Coors Beverage Company—Hop Valley Brewing, Terrapin Beer Co., Revolver Brewing, and Atwater Brewery—significantly increasing regional brewing capacity and market presence.
•Rollout of Hemp-Derived Delta-9 THC Beverage Portfolio (September 2024): Announced the strategic commercial launch of hemp-derived Delta-9 THC infused beverages across select US state markets, leveraging established craft beverage sales channels.
•Expansion in German Medical Cannabis Market (April 2024): Operationalized commercial expansion across Germany following the enactment of the Cannabis Act (CanG), resulting in consecutive months of increased medical patient prescription registrations.
•Fiscal 2026 Financial Year-End Reporting (July 2024): Concluded fiscal 2026 reporting, detailing portfolio rationalization, working capital management, and structural cost alignments following previous multi-brand acquisitions.
•Canadian Cultivation Footprint Optimization (June 2024): Completed operational adjustments across Canadian cannabis production facilities, consolidating flower cultivation into lower-cost automated facilities to improve per-gram operating efficiency.

Catalysts

•US DEA Cannabis Rescheduling Decision: Administrative completion or legal developments regarding the US Drug Enforcement Administration's proposed rule to reschedule cannabis from Schedule I to Schedule III under federal law.
•US Farm Bill Reauthorization Legislative Action: Potential legislative amendments to the US Farm Bill regarding the regulation and legality of hemp-derived cannabinoids, directly impacting Tilray's Delta-9 THC beverage strategy.
•Quarterly Sequential Progress in German Medical Cannabis: Sequential quarterly earnings releases demonstrating the pace of revenue and margin expansion in Germany following the full operationalization of the CanG deregulation.
•Canadian Federal Cannabis Act Excise Tax Review: Potential policy updates or recommendations from the Canadian federal government regarding structural adjustments to cannabis excise duty calculations.
•Fiscal Second Quarter 2027 Financial Results: Scheduled release of Q2 FY2027 earnings in January 2027, providing visibility into holiday craft beverage depletions and operational cash flow trends.

Acquisitions & Strategy

•Acquired Hop Valley Brewing Company, Terrapin Beer Co., Revolver Brewing, and Atwater Brewery from Molson Coors Beverage Company in August 2024 for an undisclosed cash purchase price to expand craft beer distribution and brewing presence across the Pacific Northwest, Southeast, and Midwest regions. Integration of production and distribution is ongoing.
•Acquired eight craft beer and beverage brands from Anheuser-Busch InBev (including Shock Top, Breckenridge Brewery, Blue Point, 10 Barrel, Redhook, Widmer Brothers, Square Mile Cider, and HiBall Energy) in October 2023 for approximately $85 million in cash to establish Tilray as the 5th largest craft brewer in the United States. Operations have been integrated into Tilray's US beverage platform.
•Acquired Montauk Brewing Company in November 2022 for approximately $56.9 million in cash and stock to strengthen beverage alcohol distribution in the New York metropolitan area and broader Northeast. Fully integrated into the beverage segment.
•Acquired SweetWater Brewing Company in December 2020 for approximately $300 million in cash and stock to establish Tilray's initial US craft beverage alcohol platform with cannabis-lifestyle crossover potential. Fully integrated into beverage operations.

Share Repurchase / Buyback Program

•No share repurchase program was active or conducted during the quarterly period ended August 31, 2026, as available cash was conserved for operational funding, capital expenditures, and strategic M&A.

RPO & Key Performance Indicators

•Net revenue rose 22.7% YoY to $257.15 million in Q1 FY2027 compared to $209.50 million in Q1 FY2026, driven primarily by inorganic craft beverage portfolio expansion.
•Gross margin improved to 30.1% in Q1 FY2027, an increase of 270 basis points compared to 27.4% in the prior-year period, supported by favorable beverage alcohol margins.
•Operating cash outflow widened to -$16.54 million in Q1 FY2027 compared to -$1.34 million in Q1 FY2026, reflecting seasonal brewing inventory builds and working capital requirements.
•Free cash flow deficit increased to -$27.55 million in Q1 FY2027 compared to -$10.86 million in Q1 FY2026, driven by operational cash burn and $11.01 million in capital expenditures.

Strengths

•Scaled US Craft Brewing Infrastructure: Established the 5th largest craft brewing platform in the United States, providing significant wholesale distribution scale across major retail chains and independent distributors.
•Leading European Medical Cannabis Footprint: Operates dual EU-GMP certified cultivation facilities in Germany and Portugal, integrated with CC Pharma's distribution access to approximately 13,000 German pharmacies.
•Diversified CPG Portfolio: Generates nearly $1 billion in trailing twelve-month revenue ($963.1 million TTM) across four non-correlated segments (Beverage Alcohol, Cannabis, Distribution, and Wellness), reducing reliance on Canadian adult-use cannabis.
•Gross Margin Expansion: Consolidated gross margin expanded 270 basis points year-over-year to 30.1% in Q1 FY2027, driven by supply chain optimizations and higher-margin craft beverage contributions.
•Canadian Recreational Brand Leadership: Maintains leading adult-use market share in Canada through well-recognized brands including Good Supply, Redecan, and Broken Coast.
•Strategic Positioning for US Regulatory Reform: Turnkey US beverage manufacturing and distribution infrastructure provides operational readiness to commercialize THC beverages upon federal regulatory relaxation.

AI Benefits & Opportunities

•Agricultural and Cultivation Yield Optimization: Deploying machine learning algorithms and environmental sensors across Canadian and European growing facilities to analyze lighting, irrigation, and nutrient parameters, optimizing crop yields and lowering per-gram production costs.
•Predictive Supply Chain and Inventory Analytics: Utilizing AI-driven demand forecasting tools to optimize inventory levels, brewing schedules, and logistics across multi-state craft beer distributor networks, mitigating excess working capital tie-ups.

Risks & Concerns for Tilray Brands Inc ($TLRY)

You're one step away

Unlock the full risk analysis

See business risks, AI filing insights, and deeper research for this stock. Create a free account to continue — includes a 14-day Pro trial.

No card required • Free plan stays after trial

About this summary

AI-generated research for Tilray Brands Inc (TLRY, filings period ending August 31, 2026). AI summaries, reports, and scoring can be inaccurate or incorrect; accuracy and correctness are not guaranteed. Informational only; not investment advice or personalized guidance.Enumerated risk factors in this view may be abbreviated for anonymous or guest sessions. Full risk sections are available with full access.

Summary generated on Oct 18, 2026.

Peers of Tilray Brands Inc (TLRY)

SNDLDeep Dive

Side-by-side comparison

SNDL

Based on August 31, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.

Latest Report Overview for Tilray Brands Inc ($TLRY)

Key Takeaways

1.Expanded US craft brewing scale by completing the acquisition and initial integration of four craft beer brands from Molson Coors (Hop Valley, Terrapin, Revolver, and Atwater) in August 2024, cementing Tilray's status as the 5th largest craft brewer in the United States.
2.First-quarter fiscal 2027 net revenue climbed 22.7% year-over-year to $257.15 million, driven primarily by double-digit expansion in the beverage alcohol portfolio and European medical cannabis demand.
3.GAAP net loss registered at -$43.14 million with diluted EPS of -$0.32, reflecting an operating margin of -6.3% as general administrative costs and excise taxes outweighed gross profit improvements.
4.Free cash flow burn continued with a deficit of -$27.55 million in Q1 FY2027, bringing trailing twelve-month free cash flow to -$118.82 million and highlighting ongoing reliance on existing cash balances.
5.Gross margin expanded by 270 basis points year-over-year to 30.1%, benefiting from product mix shifts toward higher-margin craft beverage lines and supply chain efficiencies.
6.International medical cannabis revenues experienced positive momentum in Germany following the implementation of the Cannabis Act (CanG), driving increased patient prescriptions across Tilray's pharmacy distribution network.
7.Total debt stood at $325.75 million against cash and equivalents of $214.96 million, resulting in net debt of $110.79 million and maintaining a potential dilution overhang if operational cash flow does not reach breakeven.

What They Do

How They Make Money

Competitive Position

Business Strategy & Moat

Industry Outlook

Growth Drivers

•Expanded US Craft Beverage Distribution: Driving increased retail chain distribution, taproom sales, and national draft placements for recently acquired craft beer brands (Hop Valley, Terrapin, Revolver, Atwater, Shock Top, Breckenridge, 10 Barrel) across the US three-tier distribution system.
•German Medical Cannabis Deregulation: Capitalizing on Germany's Cannabis Act (CanG), which de-scheduled cannabis from the Narcotics Act, simplifying medical prescription protocols and expanding patient volume through CC Pharma's network of 13,000 pharmacies.
•Commercialization of Hemp-Derived Delta-9 THC Beverages: Rolling out hemp-derived Delta-9 THC infused drinks and mocktails across legal US retail and direct-to-consumer channels, utilizing existing beverage manufacturing and distribution assets.
•Canadian Adult-Use Product Innovation: Launching higher-margin cannabis format extensions, including infused pre-rolls, live resin vape cartridges, and premium flower strains under flagship brands Good Supply, Redecan, and Broken Coast.
•International Medical Market Expansion: Scaling medical cannabis export sales into emerging European and international medical frameworks, including the United Kingdom, Poland, Italy, the Czech Republic, and Australia.
•Brewing and Supply Chain Consolidation: Extracting operational cost synergies and procurement savings by consolidating brewing, packaging, and logistics across centralized regional production hubs.

Recent Developments

•Acquisition of Molson Coors Craft Breweries (August 2024): Completed the strategic acquisition of four craft beer brands and brewing operations from Molson Coors Beverage Company—Hop Valley Brewing, Terrapin Beer Co., Revolver Brewing, and Atwater Brewery—significantly increasing regional brewing capacity and market presence.
•Rollout of Hemp-Derived Delta-9 THC Beverage Portfolio (September 2024): Announced the strategic commercial launch of hemp-derived Delta-9 THC infused beverages across select US state markets, leveraging established craft beverage sales channels.
•Expansion in German Medical Cannabis Market (April 2024): Operationalized commercial expansion across Germany following the enactment of the Cannabis Act (CanG), resulting in consecutive months of increased medical patient prescription registrations.
•Fiscal 2026 Financial Year-End Reporting (July 2024): Concluded fiscal 2026 reporting, detailing portfolio rationalization, working capital management, and structural cost alignments following previous multi-brand acquisitions.
•Canadian Cultivation Footprint Optimization (June 2024): Completed operational adjustments across Canadian cannabis production facilities, consolidating flower cultivation into lower-cost automated facilities to improve per-gram operating efficiency.

Catalysts

•US DEA Cannabis Rescheduling Decision: Administrative completion or legal developments regarding the US Drug Enforcement Administration's proposed rule to reschedule cannabis from Schedule I to Schedule III under federal law.
•US Farm Bill Reauthorization Legislative Action: Potential legislative amendments to the US Farm Bill regarding the regulation and legality of hemp-derived cannabinoids, directly impacting Tilray's Delta-9 THC beverage strategy.
•Quarterly Sequential Progress in German Medical Cannabis: Sequential quarterly earnings releases demonstrating the pace of revenue and margin expansion in Germany following the full operationalization of the CanG deregulation.
•Canadian Federal Cannabis Act Excise Tax Review: Potential policy updates or recommendations from the Canadian federal government regarding structural adjustments to cannabis excise duty calculations.
•Fiscal Second Quarter 2027 Financial Results: Scheduled release of Q2 FY2027 earnings in January 2027, providing visibility into holiday craft beverage depletions and operational cash flow trends.

Acquisitions & Strategy

•Acquired Hop Valley Brewing Company, Terrapin Beer Co., Revolver Brewing, and Atwater Brewery from Molson Coors Beverage Company in August 2024 for an undisclosed cash purchase price to expand craft beer distribution and brewing presence across the Pacific Northwest, Southeast, and Midwest regions. Integration of production and distribution is ongoing.
•Acquired eight craft beer and beverage brands from Anheuser-Busch InBev (including Shock Top, Breckenridge Brewery, Blue Point, 10 Barrel, Redhook, Widmer Brothers, Square Mile Cider, and HiBall Energy) in October 2023 for approximately $85 million in cash to establish Tilray as the 5th largest craft brewer in the United States. Operations have been integrated into Tilray's US beverage platform.
•Acquired Montauk Brewing Company in November 2022 for approximately $56.9 million in cash and stock to strengthen beverage alcohol distribution in the New York metropolitan area and broader Northeast. Fully integrated into the beverage segment.
•Acquired SweetWater Brewing Company in December 2020 for approximately $300 million in cash and stock to establish Tilray's initial US craft beverage alcohol platform with cannabis-lifestyle crossover potential. Fully integrated into beverage operations.

Share Repurchase / Buyback Program

•No share repurchase program was active or conducted during the quarterly period ended August 31, 2026, as available cash was conserved for operational funding, capital expenditures, and strategic M&A.

RPO & Key Performance Indicators

•Net revenue rose 22.7% YoY to $257.15 million in Q1 FY2027 compared to $209.50 million in Q1 FY2026, driven primarily by inorganic craft beverage portfolio expansion.
•Gross margin improved to 30.1% in Q1 FY2027, an increase of 270 basis points compared to 27.4% in the prior-year period, supported by favorable beverage alcohol margins.
•Operating cash outflow widened to -$16.54 million in Q1 FY2027 compared to -$1.34 million in Q1 FY2026, reflecting seasonal brewing inventory builds and working capital requirements.
•Free cash flow deficit increased to -$27.55 million in Q1 FY2027 compared to -$10.86 million in Q1 FY2026, driven by operational cash burn and $11.01 million in capital expenditures.

Strengths

•Scaled US Craft Brewing Infrastructure: Established the 5th largest craft brewing platform in the United States, providing significant wholesale distribution scale across major retail chains and independent distributors.
•Leading European Medical Cannabis Footprint: Operates dual EU-GMP certified cultivation facilities in Germany and Portugal, integrated with CC Pharma's distribution access to approximately 13,000 German pharmacies.
•Diversified CPG Portfolio: Generates nearly $1 billion in trailing twelve-month revenue ($963.1 million TTM) across four non-correlated segments (Beverage Alcohol, Cannabis, Distribution, and Wellness), reducing reliance on Canadian adult-use cannabis.
•Gross Margin Expansion: Consolidated gross margin expanded 270 basis points year-over-year to 30.1% in Q1 FY2027, driven by supply chain optimizations and higher-margin craft beverage contributions.
•Canadian Recreational Brand Leadership: Maintains leading adult-use market share in Canada through well-recognized brands including Good Supply, Redecan, and Broken Coast.
•Strategic Positioning for US Regulatory Reform: Turnkey US beverage manufacturing and distribution infrastructure provides operational readiness to commercialize THC beverages upon federal regulatory relaxation.

AI Benefits & Opportunities

•Agricultural and Cultivation Yield Optimization: Deploying machine learning algorithms and environmental sensors across Canadian and European growing facilities to analyze lighting, irrigation, and nutrient parameters, optimizing crop yields and lowering per-gram production costs.
•Predictive Supply Chain and Inventory Analytics: Utilizing AI-driven demand forecasting tools to optimize inventory levels, brewing schedules, and logistics across multi-state craft beer distributor networks, mitigating excess working capital tie-ups.

Risks & Concerns for Tilray Brands Inc ($TLRY)

You're one step away

Unlock the full risk analysis

See business risks, AI filing insights, and deeper research for this stock. Create a free account to continue — includes a 14-day Pro trial.

No card required • Free plan stays after trial

About this summary

Summary generated on Oct 18, 2026.

Latest Report Overview for Tilray Brands Inc ($TLRY)

AI-powered analysis of Tilray Brands Inc (TLRY) stock based on Q3 2026 financial data.

Published: October 18, 2026

Latest Report Overview

Key Takeaways for Tilray Brands Inc

Expanded US craft brewing scale by completing the acquisition and initial integration of four craft beer brands from Molson Coors (Hop Valley, Terrapin, Revolver, and Atwater) in August 2024, cementing Tilray's status as the 5th largest craft brewer in the United States.
First-quarter fiscal 2027 net revenue climbed 22.7% year-over-year to $257.15 million, driven primarily by double-digit expansion in the beverage alcohol portfolio and European medical cannabis demand.
GAAP net loss registered at -$43.14 million with diluted EPS of -$0.32, reflecting an operating margin of -6.3% as general administrative costs and excise taxes outweighed gross profit improvements.
Free cash flow burn continued with a deficit of -$27.55 million in Q1 FY2027, bringing trailing twelve-month free cash flow to -$118.82 million and highlighting ongoing reliance on existing cash balances.
Gross margin expanded by 270 basis points year-over-year to 30.1%, benefiting from product mix shifts toward higher-margin craft beverage lines and supply chain efficiencies.
International medical cannabis revenues experienced positive momentum in Germany following the implementation of the Cannabis Act (CanG), driving increased patient prescriptions across Tilray's pharmacy distribution network.
Total debt stood at $325.75 million against cash and equivalents of $214.96 million, resulting in net debt of $110.79 million and maintaining a potential dilution overhang if operational cash flow does not reach breakeven.

What Does Tilray Brands Inc Do?

Growth Drivers for Tilray Brands Inc

Expanded US Craft Beverage Distribution: Driving increased retail chain distribution, taproom sales, and national draft placements for recently acquired craft beer brands (Hop Valley, Terrapin, Revolver, Atwater, Shock Top, Breckenridge, 10 Barrel) across the US three-tier distribution system.
German Medical Cannabis Deregulation: Capitalizing on Germany's Cannabis Act (CanG), which de-scheduled cannabis from the Narcotics Act, simplifying medical prescription protocols and expanding patient volume through CC Pharma's network of 13,000 pharmacies.
Commercialization of Hemp-Derived Delta-9 THC Beverages: Rolling out hemp-derived Delta-9 THC infused drinks and mocktails across legal US retail and direct-to-consumer channels, utilizing existing beverage manufacturing and distribution assets.
Canadian Adult-Use Product Innovation: Launching higher-margin cannabis format extensions, including infused pre-rolls, live resin vape cartridges, and premium flower strains under flagship brands Good Supply, Redecan, and Broken Coast.
International Medical Market Expansion: Scaling medical cannabis export sales into emerging European and international medical frameworks, including the United Kingdom, Poland, Italy, the Czech Republic, and Australia.
Brewing and Supply Chain Consolidation: Extracting operational cost synergies and procurement savings by consolidating brewing, packaging, and logistics across centralized regional production hubs.

Tilray Brands Inc (TLRY) AI Stock Analysis & Earnings